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Abstract
Background: Children with congenital hearing impairment benefit from early detection and
treatment. At present, no model exists which explicitly quantifies the effectiveness of universal
newborn hearing screening (UNHS) versus other programme alternatives in terms of early
diagnosis. It has yet to be considered whether early diagnosis (within the first few months) of
hearing impairment is of importance with regard to the further development of the child compared
with effects resulting from a later diagnosis. The objective was to systematically compare two
screening strategies for the early detection of new-born hearing disorders, UNHS and risk factor
screening, with no systematic screening regarding their influence on early diagnosis.
Methods: Design: Clinical effectiveness analysis using a Markov Model.
Data Sources: Systematic literature review, empirical data survey, and expert opinion. Target
Population: All newborn babies.
Time scale: 6, 12 and 120 months.
Perspective: Health care system.
Compared Strategies: UNHS, Risk factor screening (RS), no systematic screening (NS).
Outcome Measures: Quality weighted detected child months (QCM).
Results: UNHS detected 644 QCM up until the age of 6 months (72,2%). RS detected 393 child
months (44,1%) and no systematic screening 152 child months (17,0%). UNHS detected 74,3% and
86,7% weighted child months at 12 and 120 months, RS 48,4% and 73,3%, NS 23,7% and 60,6%. At
the age of 6 months UNHS identified approximately 75% of all children born with hearing
impairment, RS 50% and NS 25%. At the time of screening UNHS marked 10% of screened healthy
children for further testing (false positives), RS 2%. UNHS demonstrated higher effectiveness even
under a wide range of relevant parameters. The model was insensitive to test parameters within
the assumed range but results varied along the prevalence of hearing impairment.
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Conclusion: We have shown that UNHS is able to detect hearing impairment at an earlier age
and more accurately than selective RS. Further research should be carried out to establish the
effects of hearing loss on the quality of life of an individual, its influence on school performance and
career achievement and the differences made by early fitting of a hearing aid on these factors.
Background
Approximately one to three per 1000 children are born
with at least moderate, bilateral hearing disorders [1-4].
Children with congenital hearing impairment benefit
from early detection and treatment of their hearing loss
[5]. The neurological development of hearing abilities
requires acoustic stimulation in the first 18 months of life.
Deficits due to lack of acoustic stimulation within the first
two years are not or not easily recovered by later rehabili-
tation. The consequences include delayed development of
speech and other cognitive and social functions. This
delay is already measurable in the first 3 years of life [6].
If disorders are detected and treated in time, either by the
use of a hearing device or cochlea implant, most of the
children develop normally and do not need additional
speech therapy [7,8]. Early diagnosis and treatment
within the sensitive time frames are therefore essential.
The German consensus conference on neonatal hearing
screening proposed diagnosis in the first 3 months and
the start of treatment in the first 6 months of life.
Various tests and test combinations with acceptable sensi-
tivity and specificity are available. Transient evoked oto-
acoustic emissions (TEOAE) or brainstem evoked
responses (BERA) can be measured. One common strat-
egy consists of a two-step TEOAE with the first measure-
ment within the first days of life and a second test a few
days later [9] (chapter 2.2.7).
While modern screening techniques for early detection are
available there is still a gap between the consensus on
detection as early as possible and the current situation.
Only 50% to 60% of children with permanent hearing
impairment are diagnosed before their second birthday
with traditional health care services [2]. While congenital
hearing loss is a serious health problem, there is little evi-
dence to support the use of routine universal screening
because of the following factors:
• as the prevalence is very low, the positive predictive
value of the tests is low
• screening technologies are still in development
• possible costs and consequences are not sufficiently
known
• benefits of early intervention are frequently expressed in
qualitative terms without presenting unbiased measures
of outcome.
In 1995 the US Preventive Services Task Force found insuf-
ficient evidence in favour of universal neonatal hearing
screening (UNHS) [10]. The Task Force proposed selective
screening of new-borns with risk factors to improve the
predictive value of the test. In the UK a national neonatal
hearing screening programme aimed at detecting bilateral
moderate to severe hearing impairments has been recom-
mended [11] and partially implemented within a pilot
project [12]. Several studies have modelled the outcomes
of UNHS versus risk factor screening [13-15]. Keren et al
[16] presented a cost-effectiveness analysis based on a
decision tree model which reported short-term effective-
ness of UNHS compared to risk factor screening.
However, there is presently no model explicitly quantify-
ing the effectiveness of UNHS versus other programme
alternatives in terms of early diagnosis, nor has it been
taken into account that diagnosis of hearing impairment
within the first few months of life is more "valuable" for
the child's further development than diagnosis later in
life. Children identified within the developmentally sen-
sitive time frame should therefore be given more weight
compared to children with delayed diagnosis.
The objective of this clinical decision analysis was to sys-
tematically compare two screening strategies for the early
detection of new-born hearing disorders: UNHS and risk
factor screening; with the option of no systematic screen-
ing regarding their influence on early diagnosis.
Our specific objectives were to show differences between
strategies expressed as the number of quality weighed
detected child months (QCM), the number of true posi-
tive cases at the age of 6 and 12 months, and the number
of false positive cases. We also wanted to investigate
which parameters had the most influence on the reported
differences and how likely these differences were.
Methods
We developed a clinical decision model to compare two
different screening strategies with the option of no sys-
tematic screening. Parameters were extracted from the lit-
erature, empirically derived from a representative patient
survey, and estimated by experts. Univariate andBMC Public Health 2005, 5:12 http://www.biomedcentral.com/1471-2458/5/12
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multivariate sensitivity analyses were performed on all rel-
evant parameters.
The decision model was used to predict absolute and
incremental effectiveness of two new-born hearing strate-
gies compared with the option of no screening in new-
born infants. For the modelling of effectiveness the rec-
ommendations of the Panel on Cost-Effectiveness in
Health and Medicine were followed [17].
Three possible strategies for neonatal hearing screening
(NHS) were evaluated:
- Universal neonatal hearing screening (UNHS): Every
hospital-born baby is screened during the first days of life.
- Risk factor screening (RS): The prevalence of hearing dis-
orders is estimated to be higher at risk groups such as chil-
dren with a positive family history, with congenital
infections, cranofacial abnormalities, low APGAR-Score
or low birth weight. This strategy screens all children with
one or more risk factors for hearing disorders.
- No systematic screening (NS): Children undergo the
usual distraction test when presented to the paediatric
service during the routine visit at the age of 12 weeks.
Some neonates are screened in the hospital, but not in a
systematic way. This reflects the present situation in Ger-
many. UNHS is performed in some maternity hospitals
and outpatient paediatric services with pilot screening
projects in several regions.
The target population of this analysis was all newborn
infants. Health effects are expressed as quality weighed
number of detected child months (QCM), and as true pos-
itive and false positive cases at certain developmentally
important ages (6 and 12 months); for example, if a hear-
ing impairment was diagnosed briefly after birth, the
infant contributed six QCM at the age of six months. If the
infant's hearing loss was diagnosed at the age of five
months, the infant added only one detected child month
at the age of six months. The term 'quality' is to reflect the
idea that the early detection of impairment is a better and
desired outcome, although there is no data on quality of
life gained by this early detection. QCM, true positives
and false positives are reported at the age of 6 and 12
months and with a time horizon of 120 months. Child
months which were added up until the age of 6 months
were multiplied with a weight of 1, child months added
after the age of 6 months were multiplied with decreasing
weighting. The derivation of this weight index is described
in the section 'data and assumptions' below. We assumed
that all children with hearing impairment would be
detected before the age of 72 months, the age of school
entry, regardless of the kind of screening strategy. In order
to give outcomes in the present more weighting, com-
pared to outcomes in the future, future effects have been
discounted at an annual rate of 3%. Discounting reflects
Table 1: Model parameters
Parameter Base case (in %) Range for 
sensitivity analysis
Source
Prevalence of new-born hearing impairment 0.15 0.09–0.3 [3], [28], [29], [4], [30], [31], [25]
Prevalence of one or more risk factors for hearing impairment 20 - [2, 25, 32]
Prevalence of hearing impairment -
In children with risk factors 0.38 - Author's calculation, [33]
In children without risk factors 0.09 - Author's calculation
Prevalence of risk factors in children with hearing impairment 50 48–56 [1, 28, 34]
Sensitivity of screening 96 96–100 [11, 32, 35]
Specificity of screening 89 77–96 [11, 32, 35]
Sensitivity of diagnostic testing 98 -
Specificity of diagnostic testing 98 -
Coverage of screening 90 85–95 Author's estimate
Follow-up after screening 80 75–85 Author's estimate
Healthy children under suspicion of hearing impairment 0.1 - Author's estimate
Discounting factor 3 per year 0–5
Weighs for quality adjustment
Time to diagnosis ≤ 6 months of age 1 - Experts'estimate
Time to diagnosis > 12 months of age 0.875
Time to diagnosis > 6 months and ≤ 12 months linear extrapolation
Probability of "natural" discovery without systematic screening Weibull Distribution 
Median age at diagnosis 
18 months
- Empirical data *)
*) author's calculations, derived from a representative survey, covering all diagnosed cases and the age of diagnosis in Upper Bavaria in 1998 and 
1999 [20]BMC Public Health 2005, 5:12 http://www.biomedcentral.com/1471-2458/5/12
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the higher value of money spent now as opposed to in the
future. Similarly, discounting also weights outcomes
experienced now (e.g., being diagnosed as true positive)
more heavily than those experienced in the future. Table
1 gives the model parameters and their references.
The decision model
We developed a state-transition (Markov) model [18]
with monthly cycles to reflect the course of disease and
diagnosis under the three screening strategies (figure 1).
Probabilistic modelling has been performed by Monte
Carlo simulations. The following health states were
possible:
- Unknown status
- Healthy (hearing) confirmed by diagnostic test and/or
screening – true negative
- Healthy (hearing) not confirmed by diagnostic test
- Hearing impaired confirmed by diagnostic test and/or
screening – true positive
- Thought to be healthy (hearing) but hearing impaired –
false negative
Health states framework of the Markov model. Arrows indicate the possible transitions Figure 1
Health states framework of the Markov model. Arrows indicate the possible transitions. "Unknown status" is the 
initial state, "True Positive" and "True Negative" are final (absorbing) states.
Unknown 
status
Not 
screened/not 
compliant
True positive 
(confirmed by 
test)
Hearing (not 
confirmed by 
test)
True negative 
(confirmed by 
test)
False positive
False 
negativeBMC Public Health 2005, 5:12 http://www.biomedcentral.com/1471-2458/5/12
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- Thought to be hearing impaired but healthy (hearing) –
false positive
- Not compliant/not followed up
The baseline cohort consisted of infants with a certain
prevalence of hearing impairment but unknown status
regarding this disorder. Screened and impaired children
are detected with the sensitivity of the screening test,
whereas screened and healthy children are classified as
healthy with the specificity of the screening test. All chil-
dren with a positive screening test (i.e., true positives and
false positives) undergo a second confirmatory diagnostic
test, unless they did not adhere to the screening or did not
present for the following tests (lost to follow-up).
Impaired children who have not been screened in the first
cycle can be diagnosed in the subsequent cycles according
to the "natural history" of diagnosis, that is, because they
don't develop speech adequately or become apparent dur-
ing the routine visits to the paediatrician. In each cycle
children can move to other health states according to the
transition probabilities. QCM are only attributed to
impaired children in whom hearing impairment is
detected. Ultimately, all impaired children of the model
cohort are diagnosed as impaired and all healthy children
are either classified as healthy or remain unclassified.
Data Professional (TreeAge Inc., Williamstown, MA) was
used to construct and run the Markov model and Excel for
Windows (Microsoft Corp.) was used to validate the
model and to perform the Monte Carlo simulations.
Data and assumptions
A pre-defined and externally reviewed literature search
was performed on new-born hearing screening using all
relevant electronic databases. Search strategy and meth-
ods have previously been reported in detail [9]. In brief,
we searched 13 medical databases including MEDLINE,
EMBASE, Current Contents for published papers and HTA
databases for published HTA reviews. Relevant articles
were identified by a combined text word and thesaurus
search. The references of the retrieved articles were then
checked for further relevant articles. We restricted our
search to publication dates from 1990 to September 2001.
Reviewed publications were scored for study quality
according to a standardised questionnaire developed by
the German Scientific Working Group Technology Assess-
ment for Health Care [19] and then either included or
excluded.
All model parameters are shown in Table 1. A two-step
screening strategy of Transient Evoked Oto-Acoustic Emis-
sions (TEOAE) was chosen as the model for screening
strategies, as this is one of the most widespread and com-
monly used technologies [9]chapter 2.2.7. The prevalence
of congenital hearing disorders in children with risk fac-
tors was calculated using the prevalence of children born
with one or more risk factors (20%) and the prevalence of
risk factors in children with congenital hearing disorders
(50%) using Bayes theorem. The probability of presenta-
tion with a falsely suspected hearing disorder in hearing
children was estimated by a panel of four clinical experts.
The probability of detection at a certain age without
screening was calculated from a representative survey,
covering all diagnosed cases and the age of diagnosis in
Upper Bavaria in 1998 and 1999 [20]. A Weibull function
for the probability to diagnosis, was fitted to the empirical
data. The slope of the weight function has been previously
estimated by experts making the following assumptions:
each month detected before the age of 6 months is
weighted with 1, assuming that children detected (and
treated) within the first 6 months of life can develop nor-
mal speech and language abilities. If not detected within
the first 12 months, profoundly and severely impaired
children will conclude with a weight of 0.85, and moder-
ately impaired children with a weight of 0.90. Presuming
that 50% of the children with permanent congenital hear-
ing disorders are moderately impaired, gives a weight of
0.875 for every month which is detected after the first
birthday. The weights between 6 and 12 months were
extrapolated in a linear fashion.
Model assumptions
Screening procedures and diagnostic procedures are based
on different biological and clinical testing principles. We
therefore assumed conditional independence of screening
procedures and subsequent diagnostic procedures.
Sensitivity analysis
In order to investigate the influence of the parameter esti-
mates on the outcome measures, one-way sensitivity anal-
yses were performed on all relevant parameters. Ranges
used for sensitivity analyses were derived from literature
searches and are shown in table 1. Multi-way probabilistic
sensitivity analysis was performed on prevalence, sensitiv-
ity, specificity, coverage and follow-up using the Monte
Carlo technique with 1,000 trials. Point estimates and
95% confidence limits were obtained by counting the
number of trials in which a certain strategy has previously
been found to be superior to the other strategies [21]. As
we assumed that UNHS will always yield more QCM than
RS or NS, we also calculated these confidence limits as a
function of the difference between strategy effectiveness.
This function results in a curve showing the cumulative
relative frequency of trials (vertical axis) yielding a certain
difference in QCM (horizontal axis) between two alterna-
tive strategies. The relative frequency gives an estimate of
the probability of a certain difference in clinical effective-
ness. The ranges for probability estimates, derived from
the literature, assumed beta distribution.BMC Public Health 2005, 5:12 http://www.biomedcentral.com/1471-2458/5/12
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Model validation
The decision model was validated on three levels:
(i) Technical validation: The model was tested independ-
ently with two different software packages (TreeAge Data
Professional and MS Excel). Routine tests (e.g., replacing
the Weibull function by a constant, setting screening
probability equal for all strategies) yielded the expected
results.
(ii) Internal validation: All data used to derive model
parameter values, were reproduced exactly by the model
(e.g., number of detected children at model end point).
(iii) External validation: The derived values are consistent
with external projections and estimates of recently pub-
lished studies which were not used in our model [16,22].
for this section.
Results
Base-case analysis
Table 2 presents the results of the base-case analysis. With
the base-case prevalence of 150 per 100,000 in a hypo-
thetical cohort of 100,000 children a maximum of 900
QCM would have been accumulated at the age of 6
months, 1800 at the age of 12 months, 18,000 at the age
of 120 months (discounted: 892, 1771, 15503), if all chil-
dren born with hearing impairment had been discovered
at birth. UNHS discovered 644 weighted child months
before the age of 6 months (72,2% of the expected value).
RS yielded 393 child months (44,1%), no systematic
screening 152 child months (17,0%). UNHS yielded
74,3% and 86,7% weighted child months at 12 and 120
months respectively, RS 48,4% and 73,3%, NS 23,7% and
60,6%. At the age of 6 months UNHS identified approxi-
mately 75% of all children born with hearing impairment,
Table 2: Results of modelling, base case assumption, for a hypothetical cohort of 100,000 children (QCM discounted at an annual 3%)
Alternative 
strategies
Expected value
Outcome UNHS RS NS
%%%
QCM at 6 months 644 72.2 393 44.1 152 17.0 892
QCM at 12 months 1315 74.3 858 48.4 420 23.7 1771
QCM at 120 months 13436 86.7 11367 73.3 9394 60.6 15503
TP at 6 months 112 74.7 74 49,3 38 25.3 150
Incremental TP at 6 months 38 36 -
TP at 120 months 150 150 150 150
FP after screening 9885 1973 - -
UNHS = universal neonatal hearing screening
RS = risk factor screening
NS = no systematic screening
QCM = quality weighed detected child months
TP = true positives
FP = false positives.
Distributions of quality weighted detected child months  (QCM, 100,000 screened children, 120 months) for newborn  hearing screening strategies evaluated by Monte Carlo simu- lation (UNHS = Universal Newborn Hearing Screening) Figure 2
Distributions of quality weighted detected child 
months (QCM, 100,000 screened children, 120 
months) for newborn hearing screening strategies 
evaluated by Monte Carlo simulation (UNHS = Uni-
versal Newborn Hearing Screening). For example, if a 
hearing impairment was diagnosed briefly after birth, the 
infant contributed six QCM at the age of six months. If the 
infant's hearing loss was diagnosed at the age of five months, 
the infant added only one detected child month at the age of 
six months.BMC Public Health 2005, 5:12 http://www.biomedcentral.com/1471-2458/5/12
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RS 50% and NS 25%. At the time of screening UNHS
marked 10% of screened healthy children for further test-
ing (false positives), RS 2%.
Sensitivity analyses
Results of sensitivity analyses are presented in table 3. All
sensitivity analyses are reported for 120 months follow
up. Resulting QCM strongly depended on the prevalence
of hearing disorders. Very low prevalence decreased the
incremental benefit of UNHS versus RS. Comparing
UNHS vs. RS, a prevalence of 9 per 1000 children yielded
a gain of 1241 QCM, a prevalence of 15 per 1000 yielded
a gain of 2027 QCM. The results were insensitive to vary-
ing assumptions about test parameters and the proportion
of children lost to follow up. A decrease in slope of the lin-
ear weighting function resulted in decreasing incremental
QCM. If detected child months were not weighted accord-
ing to time of diagnosis, UNHS would still be superior to
RS and RS to NS in terms of detected child months (data
not shown). Figure 2 shows the frequency distributions of
QCM per strategy as a result of multi-way probabilistic
sensitivity analysis. QCM was higher in UNHS compared
to RS or NS in 100% of the 1000 performed trials. Figure
3 shows the cumulative probability of obtaining a given
fixed incremental value of QCM. With a probability of
95%, UNHS resulted in a gain of at least 1200 QCM com-
pared with RS and a gain of at least 2500 QCM compared
with NS. A gain of 1200 QCM means, for example, that
200 impaired children would be positively diagnosed at
birth instead of at the age of 6 months, or that 1200
impaired children would be positively diagnosed before
the age of 5 months instead of before the age of 6 months
etc.
Discussion
We developed a decision-analytic Markov model for the
evaluation of the effectiveness of different new-born hear-
ing screening strategies. In our model, UNHS identified
Table 3: One-way sensitivity analyses for QCM at 120 months. The model was evaluated with a range of different values for one 
parameter while the other parameters were held constant. The ranges of the parameter values are given in table 1
Parameter Strategy Lower estimate Upper estimate
Prevalence
UNHS 8061 26872
RS 6820 22733
NS 5636 18787
Sensitivity of screening
UNHS 13436 13608
RS 11367 11453
NS 9394 9394
Specificity of screening
UNHS 13436 13436
RS 11367 11367
NS 9394 9394
Prevalence of risk factors in 
impaired children
UNHS 13436 13436
RS 11284 11615
NS 9394 9394
Coverage of screening
UNHS 13158 13714
RS 11204 11530
NS 9394 9394
Follow up after screening
UNHS 13177 13694
RS 11237 11496
NS 9394 9394
Discounting factor
UNHS 15725 12124
RS 13447 10180
NS 11276 8327
UNHS = universal neonatal hearing screening
RS = risk factor screening
NS = no systematic screening
QCM = quality weighed detected child monthsBMC Public Health 2005, 5:12 http://www.biomedcentral.com/1471-2458/5/12
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72% of all detectable QCM at the age of 6 months, RS
identified 44% QCM, the control group with no system-
atic screening identified 17% QCM. UNHS shows higher
effectiveness even under a wide range of additional rele-
vant parameters. QCM was introduced as a dynamic time-
to-event measure which takes into account that the age of
confirmation of congenital hearing impairments is
important for further language development. The model
results were not sensitive to test the accuracy of parameters
within the assumed range but varied with the prevalence
of hearing impairment. We have shown that UNHS leads
to an earlier age of confirmed diagnosis compared to
selective RS.
The cost effectiveness of UNHS has already been mod-
elled along secondary data [16,23,24]. This model is the
first to establish a time-dependent and quality-weighted
outcome, to introduce empirical data of the natural his-
tory of discovery and to present the results within a prob-
abilistic framework. The strength of the presented model
is that detected child months are multiplied by a weighted
function which adds more benefit per month to children
that were diagnosed before 6 months compared to those
with late detection. In the existing literature the most
interesting outcome, the proportion of children detected
early enough, has not been modelled [16].
Our findings are consistent with study results and other
projections of effectiveness. The Wessex Universal Neona-
tal Hearing Screening Trial Group found that 71 more
babies with moderate or severe hearing loss per 100 000
target population were diagnosed before the age of 6
months during periods with neonatal screening than dur-
ing periods without [25]. We found that UNHS would
yield 112 true positive cases per 100 000 as compared to
38 without systematic screening, which is a difference of
74 babies. In our model UNHS identified 28% more chil-
dren in time compared to RS. Thompson et al. estimated
this difference to be between 19% and 42% [22] and
stated that 77% of hearing impaired children would be
identified before 10 months. Keren et al. assumed that
UNHS detects 77% and RS 52% of hearing impaired chil-
dren at the age of 6 months [16]. Any differences may be
due to the fact that our function of discovery without sys-
tematic screening is more pessimistic.
Our study has several limitations. Firstly, it does not dif-
ferentiate between bilateral and unilateral hearing loss or
moderate and profound impairment. We believe, how-
ever, that even with a more refined model the differences
in effectiveness would not be substantial. Variations in the
degree of impairment would result in variations in sensi-
tivity of the test, and the model was rather insensitive to
changes of test parameters. Secondly, even though QCM
has been weighted, it is a surrogate parameter for the
actual burden of disease for the child. Preference-based
utilities have not been measured and the weighting for the
impact of early or late identification of hearing loss used
in our analysis were estimated by experts. Sensitivity anal-
yses, however, revealed that without weighing, the differ-
ence in effectiveness would still be substantial. Thirdly,
effectiveness was measured as a function of time to diag-
nosis. In routine health care, adequate treatment does not
necessarily start immediately after the diagnosis is made.
However, as knowledge on the consequences of delayed
intervention is limited, including time to intervention as
another variable in the model would have resulted in
decreased precision [22]. Fourthly, our empirical data do
not differentiate between congenital and acquired hearing
impairment. The rather pessimistic estimation of the
detection rate without screening, which might be due to
the lack of differentiation between congenital and
acquired hearing impairment, may bias the results in
favour of UNHS. Similar data, however, have been pub-
lished ([2,26], presenting a median age at diagnosis 18
months). Our estimate of discovery rate in a setting
Probability of a fixed level of incremental quality weighed  detected child months (QCM) between strategies. These  graphs are the results of a multi-way sensitivity analysis  where all model parameters were varied simultaneously  within the ranges described in table 1. They give the proba- bility that the incremental gain of QCM between two screen- ing strategies exceeds a certain value (given on the horizontal  axis) Figure 3
Probability of a fixed level of incremental quality 
weighed detected child months (QCM) between 
strategies. These graphs are the results of a multi-
way sensitivity analysis where all model parameters 
were varied simultaneously within the ranges 
described in table 1. They give the probability that 
the incremental gain of QCM between two screening 
strategies exceeds a certain value (given on the hori-
zontal axis). This reads as follows: With a probability of 
95% the difference between UNHS and RS will be 1200 
QCM or more. Results of 1000 trials of a Monte Carlo simu-
lation with a time horizon of 120 months. (UNHS = Univer-
sal Newborn Hearing Screening, RS = Risk Screening, NS = 
No Screening).BMC Public Health 2005, 5:12 http://www.biomedcentral.com/1471-2458/5/12
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without screening might be biased by regional differences
but can be easily replaced by a constant or a different rate
function adapted to other local settings. Fifthly, the
impact of late diagnosis on delayed language develop-
ment, is not yet sufficiently known [22]. The economic
effects on society in terms of lost productivity [24] and the
quality-of-life effects on individuals have been discussed
[27]. There is a lack of evidence concerning health care uti-
lization due to hearing loss and the proportion of children
following a regular school and professional career after
timely fitting of a hearing aid. Further research should be
undertaken to investigate the effect of the age of diagnosis
and intervention, on the development of hearing
impaired children and on their quality of life.
Conclusions
The value of this modelling exercise on effectiveness, lies
in the facilitation and provision of information to deci-
sion makers- by quantitatively projecting available data,
making explicit and transparent statements about
assumptions and the degree of uncertainty involved in
this area. The probability of timely intervention increases
with UNHS. UNHS can reduce age of confirmation to a
much greater extent than RS. In further studies, our model
can be used to predict costs of real life situations to evalu-
ate whether programme implementation costs would sur-
pass cost-effectiveness thresholds. Policy makers can also
base their decisions on the incremental effectiveness of
UHNS, by introducing a screening programme. The
model shows how likely an outcome is under the assump-
tion of parameter uncertainty.
In our model UNHS showed higher clinical effectiveness
compared to RS and NS. The strength of our model lies in
the naturalistic and generic structure, which makes it use-
ful as a model for further evaluation. The model gives
explicit, transparent and quantitative information about
the effectiveness of different screening strategies for policy
makers who have to decide on the potential impact of
neonatal screening. The model presented here is easily
adaptable to different settings. It will and should be veri-
fied and tested with longitudinal data of ongoing trials
and model projects.
This can be one of the first steps towards the needed trans-
parency concerning universal new-born hearing
screening.
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